Astellas Eschews Foreign Acquisitions As Rivals Go On Buying Spree
This article was originally published in PharmAsia News
Executive Summary
While other Japanese drug makers embarked on an acquisition spree the past year, Astellas Pharma has remained on the sidelines. The company did so even though two of its major drugs that together account for a third of its annual revenues have either lost their patent protection already or soon will do so. Astellas says it is considering licensing agreements as well as acquisitions to build its pipeline in several areas, but one analyst said the firm, despite its $3 billion in cash, still needs to find an acquisition target that works for it. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.